Old Web
English
Sign In
Acemap
>
Paper
>
P3.01-072 Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced EGFR+ NSCLC in Japanese Patients (ARCHER 1050)
P3.01-072 Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced EGFR+ NSCLC in Japanese Patients (ARCHER 1050)
2017
K. Nakagawa
Fumiyoshi Ohyanagi
Terufumi Kato
Toshiaki Takahashi
Hiroyasu Kaneda
Naoyuki Nogami
Seiji Niho
Noboru Yamamoto
Yoshihiko Fujita
H. Zhang
Eric Sbar
T. Wang
R. Linke
Fumito. Tsuji
T. Mok
Keywords:
Gefitinib
Oncology
Dacomitinib
Internal medicine
Medicine
first line treatment
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI
[]